Table 3.
Stimulant use and negative affect outcomes as a function of treatment condition.
| Baseline (n=63) |
Week 12 (n=43) |
Week 16 (n=44) |
||
|---|---|---|---|---|
| N (%) stimulant free UDS | ||||
| Overall sample | 41 (65.0%) | 28 (64.1%) | 26 (59.1%) | |
| MBRP | ||||
| Individuals with Major Depressive Disorder | 62.1% | 87.5% | 100% | |
| Individuals with Generalized Anxiety Disorder | 40.0% | 66.6% | 96.0% | |
| Health ED | ||||
| Individuals with Major Depressive Disorder | 60.0% | 62.5% | 50.0% | |
| Individuals with Generalized Anxiety Disorder | 33.3% | 33.3% | 60.0% | |
| Secondary outcomes M(SD) | ||||
| Depression (BDI) | ||||
| Overall sample | 15.1 (11.5) | 8.7 (11.2) | 6.8 (7.9) | |
| MBRP (49.2%) | 14.5 (9.6) | 5.3 (7.2) | 4.7 (6.9) | |
| Health Ed (50.8%) | 15.6 (12.9) | 12.0 (13.4) | 9.0 (8.5) | |
| Anxiety (BAI) | ||||
| Overall sample | 9.8 (9.1) | 6.8 (11.8) | 5.9 (9.2) | |
| MBRP(49.2%) | 9.1 (8.7) | 5.2 (9.2) | 3.2 (7.4) | |
| Health Ed (50.8%) | 10.4 (9.6) | 8.3 (13.9) | 9.0 (10.2) | |